An interventional study of Robotic-Assisted Fusion Biopsy and Expert Cognitive Fusion Biopsy in Prostate Biopsy, sponsored by Shanghai East Hospital. Not yet recruiting at 1 site in China. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Shanghai East Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI).
While MRI-guided prostate biopsies are highly effective, carrying them out in men with obesity can be physically challenging for doctors. Extra pelvic tissue increases the depth the biopsy needle must travel and makes it difficult to manually hold the ultrasound probe perfectly steady. This physical difficulty might cause doctors to miss some aggressive prostate cancers.
This study tests whether a robotic arm-which completely locks the biopsy needle on target and eliminates human hand tremors-can improve cancer detection. The study will enroll up to 570 men with high BMI who have suspicious areas on their prostate MRI. Participants will be randomly assigned to receive either a robotic-assisted biopsy or a standard manual biopsy performed by an expert urologist.
To ensure the results are completely unbiased, participants will not know which method is being used on them. They will be placed behind a surgical drape and wear noise-canceling headphones playing music during the procedure to block out the sounds of the robotic motors. The main goal is to see if the robotic method safely and significantly increases the detection rate of clinically significant prostate cancer in this specific group of patients.
The integration of multiparametric magnetic resonance imaging (mpMRI) with transperineal targeted biopsy has established a new standard for prostate cancer diagnosis. However, clinical evidence, including findings from the previous IMAGINATION trial, suggests that the diagnostic accuracy of manual targeted biopsy techniques degrades in patients with high Body Mass Index (BMI). Deep perineal adiposity creates a "hostile anatomical environment" and a "fulcrum effect" that amplifies manual tremor.
The ROBUST (Robotic Optimization for Biopsy Under Substantial Tissue) trial is an investigator-initiated, multicentre, randomised, participant- and outcome-assessor-blinded superiority trial. It uses a frequentist group-sequential design to test whether robotic-assisted fusion biopsy is superior to expert cognitive fusion biopsy for participant-level detection of clinically significant prostate cancer (ISUP grade group ≥2) in men with obesity.
To isolate the impact of mechanical stabilization from operator inexperience, the control arm represents "peak human performance": operators must be credentialed experts with >500 total prostate biopsies, including >200 cognitive fusion targeted cases.
To reduce performance and detection bias, participants are blinded using a high surgical drape and noise-cancelling headphones; pathologists and data analysts remain blinded until database lock. Operating urologists cannot be blinded.
An independent DSMB will conduct formal interim analyses at approximately 25%, 50%, and 75% of maximum primary-outcome information (approximately 128, 256, and 384 evaluable participants), with the final analysis at 100% (approximately 510). A Lan-DeMets alpha-spending function with O'Brien-Fleming-type efficacy boundaries preserves the overall one-sided type I error rate at 0.025. Futility monitoring is non-binding and based on conditional power (threshold 20%). A prespecified Bayesian analysis of the primary estimand will be performed as a supportive analysis only and will not guide stopping decisions.
Shanghai East Hospital is the lead sponsor of 95 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Robotic-Assisted Fusion Biopsy
Procedure: Robotic-Assisted Fusion Biopsy
Expert Cognitive Fusion Biopsy
Procedure: Expert Cognitive Fusion Biopsy
Participants in this arm will undergo a transperineal prostate biopsy utilizing a dedicated robotic fusion platform. The system features a mechanical arm or rigid fixator that completely locks the ultrasound probe and needle guide into a pre-planned coordinate trajectory. This mechanical stabilization uncouples the needle guide from manual human force, eliminating operator hand tremor and the "fulcrum effect" caused by deep pelvic adiposity. The urologist will obtain 3 to 4 targeted cores per MRI-visible lesion (PI-RADS ≥ 3) using the robotic interface, followed by a standard systematic biopsy. To prevent performance bias and placebo effects, participants will be blinded to the intervention using a high surgical drape and noise-canceling headphones.
Participants in this arm will undergo a standard manual transperineal prostate biopsy. To represent "peak human performance," the procedure will be performed exclusively by an expert urologist credentialed with a documented history of \>500 total prostate biopsies, including \>200 cognitive fusion targeted cases. The operator will mentally register the MRI lesion onto the real-time ultrasound image using anatomical landmarks, without the aid of any software overlay or robotic mechanical stabilization. The urologist will manually obtain 3 to 4 targeted cores per MRI-visible lesion (PI-RADS ≥ 3), followed by a standard systematic biopsy. To maintain the participant- and outcome-assessor-blinded, participants will be shielded by a surgical drape and wear noise-canceling headphones.
Detection Rate of Clinically Significant Prostate Cancer (csPCa) by Targeted Biopsy
The primary efficacy endpoint is the proportion of participants in the intention-to-treat (ITT) population diagnosed with clinically significant prostate cancer (csPCa) specifically from the targeted biopsy cores. csPCa is strictly defined histopathologically as International Society of Urological Pathology (ISUP) Grade Group 2 or higher (Gleason score 3+4=7 or greater).
Time frame: Up to 30 days post-procedure (at the time of final pathology report)
Detection Rate of Any Prostate Cancer by Targeted Biopsy
The proportion of participants in whom any prostate cancer, defined as ISUP Grade Group 1 or higher (Gleason score 3+3=6 or greater), is detected specifically from the targeted biopsy cores.
Time frame: Up to 30 days post-procedure
Detection Rate of csPCa by Combined Biopsy
The proportion of participants diagnosed with clinically significant prostate cancer (ISUP Grade Group 2 or higher) when combining the pathological results from both the targeted biopsy cores and the standard systematic biopsy cores.
Time frame: Up to 30 days post-procedure
Pathological Upgrade Rate
The proportion of participants in whom the targeted biopsy cores detect a higher ISUP Grade Group of prostate cancer compared to the ISUP Grade Group detected by the background systematic biopsy cores in the same patient.
Time frame: Up to 30 days post-procedure
Incidence of Adverse Events (CTCAE v5.0)
Incidence of adverse events graded according to CTCAE v5.0, including adverse events of special interest (gross haematuria requiring catheterisation/irrigation, urinary retention, febrile urinary tract infection, vasovagal syncope) and obesity-related complications (e.g., perineal haematoma).
Time frame: Up to 30 days post-procedure
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in the primary publication, along with the study protocol and statistical analysis plan (SAP), will be made available to qualified scientific researchers. Data will be available beginning 6 months and ending 36 months following article publication. To gain access, researchers must submit a methodologically sound study proposal to the corresponding authors. Data sharing will be strictly subject to the execution of a formal data use agreement and must fully comply with local institutional review board (IRB) requirements and national data security regulations regarding cross-border data transfer.
Supporting information: Study protocol
Time frame: 1 year after publication
Access criteria: kuohaiandrew2000@vip.sina.com
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start May 2026 → Jan 2027, primary completion May 2028 → Jan 2029 and completion May 2028 → Feb 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai East Hospital